INT48088

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 1995
Last Reported 2010
Negated 1
Speculated 6
Reported most in Body
Documents 12
Total Number 20
Disease Relevance 4.93
Pain Relevance 8.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Grm8) signal transducer activity (Grm8)
Anatomy Link Frequency
neurons 4
glial cells 1
Grm8 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Glutamate 245 100.00 Very High Very High Very High
agonist 218 100.00 Very High Very High Very High
Glutamate receptor 44 100.00 Very High Very High Very High
antagonist 133 99.92 Very High Very High Very High
Pain 103 99.82 Very High Very High Very High
nMDA receptor 6 99.80 Very High Very High Very High
cocaine 4 99.50 Very High Very High Very High
Eae 4 99.24 Very High Very High Very High
Dopamine 73 99.20 Very High Very High Very High
Periaqueductal grey 5 98.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nociception 28 100.00 Very High Very High Very High
Ganglion Cysts 12 99.56 Very High Very High Very High
Neuropathic Pain 9 99.24 Very High Very High Very High
Urological Neuroanatomy 14 98.92 Very High Very High Very High
Epilepsy 4 98.28 Very High Very High Very High
Disease 260 98.20 Very High Very High Very High
Pain 100 95.04 Very High Very High Very High
Arthritis 74 94.84 High High
Depression 79 87.56 High High
Hypokinesia 4 80.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effect of the mGluR(5) antagonist, MPEP (2-Methyl-6-(phenylethynyl)-pyridine), and of the mGluR(1) antagonist, AIDA((RS)-1-Aminoindan-1,5-dicarboxylic acid), were examined on nociceptive neurons in the ventroposterolateral (VPL) nucleus of the thalamus in response to pressure stimuli to the contralateral hindpaw of rats under urethane anesthesia.
Spec (examined) Regulation (effect) of mGluR in neurons associated with nociception, anesthesia, antagonist, vpl thalamus and thalamus
1) Confidence 0.62 Published 2000 Journal Brain Res. Section Abstract Doc Link 10899289 Disease Relevance 0.17 Pain Relevance 0.28
The tight-seal whole cell recording technique was used to study the effects of the metabotropic glutamate receptor (mGluR) agonist, trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) on spontaneous gamma-aminobutyric acid (GABA)-mediated synaptic currents in neonatal rat CA1 hippocampal neurons in slices obtained from postnatal (P) days P6-P12. 2.
Regulation (effects) of mGluR in neurons associated with gaba, glutamate receptor and agonist
2) Confidence 0.60 Published 1995 Journal J. Neurophysiol. Section Abstract Doc Link 7500137 Disease Relevance 0 Pain Relevance 0.28
CONCLUSION: Both mGluR5 and mGluR1 antagonists are effective in models of pain and anxiety.
Regulation (effective) of mGluR
3) Confidence 0.44 Published 2005 Journal Psychopharmacology (Berl.) Section Body Doc Link 15682298 Disease Relevance 0 Pain Relevance 0
Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats.
Regulation (effective) of mGluR associated with pain, eae and agonist
4) Confidence 0.44 Published 2002 Journal Pharmacol. Biochem. Behav. Section Title Doc Link 12117597 Disease Relevance 0.77 Pain Relevance 1.20
OBJECTIVES: This study was conducted to investigate the role of the mGluR5 and mGluR1 subtypes in the modulation of pain and anxiety.
Regulation (role) of mGluR
5) Confidence 0.44 Published 2005 Journal Psychopharmacology (Berl.) Section Body Doc Link 15682298 Disease Relevance 0 Pain Relevance 0
The effects of metabotropic glutamate receptor (mGluR) activation on non-dopamine (putative GABAergic) neurons and inhibitory synaptic transmission in the ventral tegmental area were examined using intracellular recordings from rat midbrain slices.
Spec (examined) Regulation (effects) of mGluR in neurons associated with ventral tegmentum, dopamine, gabaergic, glutamate receptor and midbrain
6) Confidence 0.43 Published 2003 Journal Neuroscience Section Abstract Doc Link 12770559 Disease Relevance 0 Pain Relevance 0.42
The effects of an NMDA (N-methyl-D-aspartate), non-NMDA or metabotropic glutamate receptor (mGluR) antagonist microinjected into Sm on the TF reflex were examined in untreated or in Sm glutamate treated (microinjection into the Sm) rats.
Spec (examined) Regulation (effects) of mGluR associated with glutamate, antagonist, glutamate receptor and tail-flick
7) Confidence 0.34 Published 2003 Journal Brain Res. Section Abstract Doc Link 14519536 Disease Relevance 0 Pain Relevance 0.72
Results obtained with a nitric oxide (NO) donor, NO synthase inhibitors, metabotropic glutamate receptor (mGluR) agonist and mGluR1 antagonist, and a glial metabolism inhibitor suggest that after conditioning, presynaptic excitation is facilitated by NO released from glial cells via the activation of mGluR1.
Neg (NO) Regulation (metabotropic) of mGluR in glial cells associated with antagonist, glutamate receptor and agonist
8) Confidence 0.28 Published 2004 Journal J. Neurosci. Section Abstract Doc Link 15525773 Disease Relevance 0.22 Pain Relevance 0.86
Kinetic analyses revealed no differences in the distribution of rise and decay times of mEPSCs (P>0.5 in both cases, KS; data not shown), supporting the conclusion that the effects of the mGluR agonist on IEI were due to presynaptic modulation of glutamate release.


Regulation (effects) of mGluR associated with glutamate and agonist
9) Confidence 0.22 Published 2007 Journal Neuroscience Section Body Doc Link PMC2504724 Disease Relevance 0 Pain Relevance 0.33
Here, we examined the effect of the potent agonist of group III mGluR, ACPT-1 (20 ?
Spec (examined) Regulation (effect) of mGluR associated with agonist
10) Confidence 0.22 Published 2007 Journal Neuroscience Section Body Doc Link PMC2504724 Disease Relevance 0 Pain Relevance 0.56
To examine the role of Siah1a expression on mGluR function, SCG neurons were injected with cDNA encoding several group I mGluRs (mGluR1, 5 and their splice variants) with or without Siah1a expression.
Spec (examine) Regulation (role) of mGluR in neurons associated with ganglion cysts
11) Confidence 0.21 Published 2001 Journal BMC Neurosci Section Body Doc Link PMC58838 Disease Relevance 0.26 Pain Relevance 0.11
Chronic cocaine treatment abolished the effects of group II mGluR agonists on synaptic transmission while increased potencies of group II mGluR agonists were observed in the kindling model of epilepsy [34,35].
Regulation (effects) of mGluR associated with epilepsy, agonist and cocaine
12) Confidence 0.19 Published 2006 Journal Mol Pain Section Body Doc Link PMC1471776 Disease Relevance 0.53 Pain Relevance 0.74
These data suggest that group II mGluR function depends on the type or origin of neuroplasticity and is modulated differently than that of group III mGluRs.
Regulation (modulated) of mGluR
13) Confidence 0.13 Published 2006 Journal Mol Pain Section Body Doc Link PMC1471776 Disease Relevance 0.65 Pain Relevance 0.92
Siah1a attenuated heterologously expressed group I mGluR-mediated calcium current inhibition, but was without effect on group II mGluR- or NE-mediated calcium current modulation via heterologously expressed mGluR2 or native a2 adrenergic receptors, respectively, indicating that the effect of Siah was specific for group I mGluRs.
Regulation (modulation) of mGluR
14) Confidence 0.11 Published 2001 Journal BMC Neurosci Section Abstract Doc Link PMC58838 Disease Relevance 0.09 Pain Relevance 0.12
The unrecognized presence of such effects could explain some controversial findings regarding mGluR control of synaptic transmission that have been reported.
Regulation (control) of mGluR
15) Confidence 0.08 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2699468 Disease Relevance 0 Pain Relevance 0.29
This study suggests that endogenous glutamate could tonically modulate nociception through mGlu and NMDA receptors in the PAG matter.
Regulation (modulate) of mGlu associated with nociception, glutamate, periaqueductal grey and nmda receptor
16) Confidence 0.01 Published 2001 Journal Neuropharmacology Section Abstract Doc Link 11166324 Disease Relevance 0.35 Pain Relevance 0.89
This variability makes it difficult to predict the likely outcome of targeting group III mGlu receptors in the SNr in the early stages of PD.
Spec (likely) Regulation (targeting) of mGlu associated with disease
17) Confidence 0.01 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989582 Disease Relevance 0.34 Pain Relevance 0.28
However, in light of recent advances in available compounds targeting group III mGlu receptors (e.g.
Regulation (targeting) of mGlu
18) Confidence 0.01 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989582 Disease Relevance 0.39 Pain Relevance 0.13
Clearly, it will be essential to establish at what level of lesion development the detrimental effects of targeting group III mGlu receptors in the SNr are replaced by the beneficial ones, or indeed which group III mGlu receptor subtype might be responsible for the detrimental effects, before the full impact of this finding is realized.
Regulation (targeting) of mGlu
19) Confidence 0.01 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989582 Disease Relevance 0.30 Pain Relevance 0.24
Chaudhuri and Schapira, 2009), this review will explore recent advances in targeting group III metabotropic glutamate (mGlu) receptors for the treatment of the classical motor symptoms.
Regulation (targeting) of mGlu associated with glutamate
20) Confidence 0.01 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989582 Disease Relevance 0.86 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox